Get involved in the discussion! Click here to comment on this story
Biodesix and Immodulon have announced a joint venture into biomarker research. The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-101 using the Biodesix Diagnostic Cortex machine learning platform.
The Biodesix proprietary machine learning platform “builds on recent advances in the artificial intelligence field to uncover clinically relevant and elaborate biomarker patterns and relationships.” This In turn enables personalised approaches to therapy selection and a better understanding of complex diseases like cancer. IMM-101 is Immodulon’s investigational immunotherapeutic candidate under development for various tumour types, including advanced pancreatic cancer.
Dr Jaap Kampinga, Immodulon’s CEO, said that in the IMAGE I randomised clinical trial, metastatic pancreatic cancer patients receiving IMM-101 and gemcitabine benefitted from a “59% increase in median overall survival compared to those receiving gemcitabine alone.”
He continued, “There was considerable variability, as is typical in pancreatic cancer, with some patients surviving much longer than others. From this collaboration and by utilising the Biodesix Diagnostic Cortex in identifying blood-based proteomic biomarkers, we hope to facilitate selection of those patients most likely to respond to IMM-101. This could improve the efficiency of treatment and patient care, and accelerate our clinical trial programmes.”
Immodulon recently appointed Thomas O. Kleen as chief scientific officer of the Company.
By: Anna Smith
Source: Pharma Times
LinkedIn Twitter FacebookThe health care industry will continue to be transformed by the role of Big Data, DexCom CEO Kevin Sayer told CNBC’s Jim Cramer on Wednesday. “This whole integration […]
LinkedIn Twitter FacebookAerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other […]
LinkedIn Twitter FacebookIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was […]